2015
Obstetric and Neonatal Outcomes After Antipsychotic Medication Exposure in Pregnancy
Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and Neonatal Outcomes After Antipsychotic Medication Exposure in Pregnancy. Obstetrics And Gynecology 2015, 125: 1224-1235. PMID: 25932852, PMCID: PMC4418034, DOI: 10.1097/aog.0000000000000759.Peer-Reviewed Original ResearchConceptsAdverse birth outcomesGestational-age birthsAntipsychotic exposureNeonatal outcomesCohort studyBirth outcomesAntipsychotic medicationMajor malformationsBirth weightOdds ratioAntipsychotic medication exposureNeonatal birth weightPooled odds ratioPotential risk factorsUnexposed pregnanciesMedication exposurePreterm deliveryGestational ageAntipsychotic treatmentElective terminationPossible confoundersReproductive ageRisk factorsSpontaneous abortionSTUDY SELECTION
2004
Management of Bipolar Disorder During Pregnancy and the Postpartum Period
Yonkers KA, Wisner KL, Stowe Z, Leibenluft E, Cohen L, Miller L, Manber R, Viguera A, Suppes T, Altshuler L. Management of Bipolar Disorder During Pregnancy and the Postpartum Period. American Journal Of Psychiatry 2004, 161: 608-620. PMID: 15056503, DOI: 10.1176/appi.ajp.161.4.608.Peer-Reviewed Original ResearchConceptsMood stabilizersBipolar disorderPostpartum periodFuture reproductive plansBipolar disorder patientsIssue of pregnancyPeripartum womenCohort studyPostpartum womenPregnant womenSodium valproateDisturbed sleepReproductive yearsHuman teratogenPsychotic componentsGeneral populationDisorder patientsPregnancyConsensus documentAmerican Psychiatric AssociationReproductive plansDisordersEarly adulthoodExpert panelWomen